一种新药,萨基图祖马布,在一项大型试验中改善了晚期三阴性乳腺癌患者的生存率和生活质量. A new drug, sacituzumab, improved survival and quality of life for advanced triple-negative breast cancer patients in a major trial.

第3阶段的试验发现,acistuzumab govitecan在对高级三阴性乳腺癌的第一线治疗中大大改善了无进展的存活率,接受化疗的中位数为9.7个月,而中位数为6.9个月。 A phase 3 trial found sacituzumab govitecan significantly improved progression-free survival in first-line treatment for advanced triple-negative breast cancer, with a median of 9.7 months versus 6.9 months for chemotherapy. 病人的生活质量也得到改善,尽管胃肠道副作用增加,但身体功能保持更长。 Patients also experienced better quality of life, maintaining physical function longer despite higher gastrointestinal side effects. 虽然总体生存数据因交叉而尚不成熟,但随着抗菌素的出现,第二次进展的时间较长。 While overall survival data were immature due to crossover, time to second progression was longer with sacituzumab. 在一次单独的荷尔蒙受体阳性乳腺癌试验中,acistuzumab没有达到其主要的PFS终点,但显示出一种改善生存和有利于调查人员评估的结果的趋势。 In a separate trial for hormone receptor-positive breast cancer, sacituzumab did not meet its primary PFS endpoint but showed a trend toward improved survival and favorable investigator-assessed outcomes.